6.31

2.62% -0.17

Myriad Genetics Inc (MYGN)

Overview News Price History Option Chain Financials Why MYGN Down? Discussions Forecast Stock Split

Myriad Genetics Inc stock is traded at $6.31, with a volume of 658.60K. It is down -2.62% in the last 24 hours and down -17.30% over the past month. Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Previous Close:

$6.48

Open:

$6.57

24h Volume:

658.60K

Relative Volume:

0.62

Market Cap:

$588.18M

Revenue:

$823.60M

Net Income/Loss:

$-116.00M

P/E Ratio:

-4.8538

EPS:

-1.3

Net Cash Flow:

$-107.30M

1W Performance:

-6.66%

1M Performance:

-17.30%

6M Performance:

+20.19%

1Y Performance:

-52.98%

1-Day Range:

$6.29

$6.57

1-Week Range:

$6.29

$6.77

52-Week Range:

$3.76

$15.47

Myriad Genetics Inc Stock (MYGN) Company Profile

Name

Myriad Genetics Inc

Sector

Healthcare (1131)

Industry

Diagnostics & Research (54)

Phone

801-584-3600

Address

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Employee

2,700

Twitter

@myriadgenetics

Next Earnings Date

2025-02-24

Latest SEC Filings

MYGN's Discussions on Twitter

Compare MYGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MYGN Myriad Genetics Inc	6.31	604.02M	823.60M	-116.00M	-107.30M	-1.30
TMO Thermo Fisher Scientific Inc	585.07	218.19B	43.74B	6.58B	6.11B	17.31
DHR Danaher Corp	230.63	162.69B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	687.89	54.98B	4.17B	1.03B	940.22M	12.61
A Agilent Technologies Inc	137.93	39.23B	6.95B	1.30B	1.15B	4.5696
IQV Iqvia Holdings Inc	227.11	38.64B	15.90B	1.28B	2.21B	7.2842

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-21-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
May-08-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-09-25	Downgrade	Guggenheim	Buy → Neutral
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight
Feb-12-25	Initiated	Craig Hallum	Buy
Dec-10-24	Initiated	UBS	Neutral
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Underperform
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform
Dec-21-23	Resumed	Piper Sandler	Neutral
Dec-19-23	Initiated	Wells Fargo	Equal Weight
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Jul-05-23	Resumed	JP Morgan	Underweight
May-23-23	Upgrade	Goldman	Sell → Buy
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform
Oct-06-22	Initiated	Stephens	Equal-Weight
Oct-15-21	Resumed	Cowen	Market Perform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy
Jan-03-19	Initiated	Needham	Strong Buy
Nov-30-18	Upgrade	Goldman	Sell → Neutral
Oct-10-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-11-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-21-18	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-29-18	Initiated	Goldman	Sell
Jan-22-18	Reiterated	Barclays	Equal Weight
Jan-05-18	Initiated	BTIG Research	Buy
Oct-02-17	Resumed	Leerink Partners	Mkt Perform
Aug-09-17	Reiterated	Barclays	Equal Weight
Feb-08-17	Upgrade	Ladenburg Thalmann	Sell → Neutral
Jan-18-17	Initiated	Deutsche Bank	Sell
Oct-10-16	Downgrade	Ladenburg Thalmann	Neutral → Sell

View All

Myriad Genetics Inc Stock (MYGN) Latest News

12:28 PM

Pancreatic Cancer Market is projected to reach US$ 5.7 billion - openPR.com

12:28 PM

Dec 29, 2025

Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN

Dec 29, 2025

Dec 25, 2025

Looking at the Narrative for Myriad Genetics After Price Target Revisions and Growth Concerns - Yahoo Finance

Dec 25, 2025

Dec 22, 2025

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz

Dec 22, 2025

Can Myriad Genetics Inc. stock sustain revenue growth2025 Macro Impact & Low Volatility Stock Recommendations - Улправда

Dec 22, 2025

Dec 21, 2025

Is Myriad Genetics Inc a good long term investmentPrice Volatility Patterns & Don’t Miss These Undervalued Stocks - earlytimes.in

Dec 21, 2025

Avoiding Lag: Real-Time Signals in (MYGN) Movement - news.stocktradersdaily.com

Dec 21, 2025